TREACE JOHN R 4
4 · TREACE MEDICAL CONCEPTS, INC. · Filed May 11, 2022
Insider Transaction Report
Form 4
TREACE JOHN R
Director
Transactions
- Sale
Common Stock
2022-05-09$13.30/sh−37,312$496,190→ 1,860,478 total(indirect: John R. Treace and Ginger D. Treace JTTEN) - Sale
Common Stock
2022-05-09$15.22/sh−18,415$280,197→ 1,823,097 total(indirect: John R. Treace and Ginger D. Treace JTTEN) - Sale
Common Stock
2022-05-09$14.20/sh−18,966$269,387→ 1,841,512 total(indirect: John R. Treace and Ginger D. Treace JTTEN) - Sale
Common Stock
2022-05-09$15.97/sh−307$4,902→ 1,822,790 total(indirect: John R. Treace and Ginger D. Treace JTTEN)
Holdings
- 408,816(indirect: By Trust)
Common Stock
Footnotes (6)
- [F1]Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.93 to $13.86 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $13.93 to $14.86 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.93 to $15.891 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.96 to $15.97 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The Reporting Person disclaims beneficial ownership of shares held in trusts for which his spouse is a co-trustee.